Related references
Note: Only part of the references are listed.Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway
Wei Xu et al.
CANCER LETTERS (2015)
An Inhibitor's-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States
Aude Echalier et al.
ACS CHEMICAL BIOLOGY (2014)
Fluorescent biosensors for high throughput screening of protein kinase inhibitors
Camille Prevel et al.
BIOTECHNOLOGY JOURNAL (2014)
Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells
Bin Jia et al.
CANCER LETTERS (2014)
Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers
Alison M. Karst et al.
CANCER RESEARCH (2014)
Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
Mark A. Dickson
CLINICAL CANCER RESEARCH (2014)
Fluorescent biosensors for drug discovery new tools for old targets - Screening for inhibitors of cyclin-dependent kinases
Camille Prevel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARKS)
M. V. Ramana Reddy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer.
S. Kim et al.
MOLECULAR CANCER THERAPEUTICS (2014)
High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma
Simi Santala et al.
TUMOR BIOLOGY (2014)
Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3β and CDK5 following traumatic brain injury
Sarah M. Wilson et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2014)
SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression
Anita C. Bellail et al.
NATURE COMMUNICATIONS (2014)
Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73
Frankie Lam et al.
ONCOTARGET (2014)
Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling
Silvia Park et al.
SCIENTIFIC REPORTS (2014)
Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features
Zhizhou Fang et al.
ACS CHEMICAL BIOLOGY (2013)
Kinase Drug Discovery - What's Next in the Field?
Philip Cohen et al.
ACS CHEMICAL BIOLOGY (2013)
Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology
Chao Zhang et al.
ACS CHEMICAL BIOLOGY (2013)
Emerging roles of Cdk8 in cell cycle control
Zsolt Szilagyi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2013)
Potent inhibitors of CDK5 derived from roscovitine: Synthesis, biological evaluation and molecular modelling
Luc Demange et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
A novel CyclinE/CyclinA-CDK Inhibitor targets p27Kip1 degradation, cell cycle progression and cell survival: Implications in cancer therapy
Lu Dai et al.
CANCER LETTERS (2013)
Tumor-suppressive effects of CDK8 in endometrial cancer cells
Weiting Gu et al.
CELL CYCLE (2013)
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard et al.
CLINICAL CANCER RESEARCH (2013)
Targeting cyclin-dependent kinases in anti-neoplastic therapy
Celine Bruyere et al.
CURRENT OPINION IN CELL BIOLOGY (2013)
Anticancer Therapeutic Strategies Based on CDK Inhibitors
Luca Esposito et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Shuhui Lim et al.
DEVELOPMENT (2013)
ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
Agnese Anna Abate et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice
Varsha Shukla et al.
FASEB JOURNAL (2013)
A Chrysin Derivative Suppresses Skin Cancer Growth by Inhibiting Cyclin-dependent Kinases
Haidan Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Specific Inhibition of p25/Cdk5 Activity by the Cdk5 Inhibitory Peptide Reduces Neurodegeneration In Vivo
Jeyapriya Raja Sundaram et al.
JOURNAL OF NEUROSCIENCE (2013)
Blockbuster dreams for Pfizer's CDK inhibitor
Malini Guha
NATURE BIOTECHNOLOGY (2013)
Inhibition of α-helix-mediated protein-protein interactions using designed molecules
Valeria Azzarito et al.
NATURE CHEMISTRY (2013)
CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome
Vincent J. Guen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression
Qian Liang et al.
SCIENTIFIC REPORTS (2013)
A Defect of the INK4-Cdk4 Checkpoint and Myc Collaborate in Blastoid Mantle Cell Lymphoma-Like Lymphoma Formation in Mice
Christelle Vincent-Fabert et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors
Mei-Chu Lo et al.
ANALYTICAL BIOCHEMISTRY (2012)
Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma
H. Miyagaki et al.
BRITISH JOURNAL OF CANCER (2012)
CDK8 Maintains Tumor Dedifferentiation and Embryonic Stem Cell Pluripotency
Adam S. Adler et al.
CANCER RESEARCH (2012)
Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients
Zachary Levacque et al.
CELL CYCLE (2012)
Going out of the brain: Non-nervous system physiological and pathological functions of Cdk5
Erick Contreras-Vallejos et al.
CELLULAR SIGNALLING (2012)
Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation
Zhenfeng Duan et al.
CLINICAL CANCER RESEARCH (2012)
A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors
B. O. Villoutreix et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
A Novel Mechanism for Regulating Hepatic Glycogen Synthesis Involving Serotonin and Cyclin-Dependent Kinase-5
Susan J. Tudhope et al.
DIABETES (2012)
Cdk1 interplays with Oct4 to repress differentiation of embryonic stem cells into trophectoderm
Lei Li et al.
FEBS LETTERS (2012)
Clinical and biological significance of Cdk10 in hepatocellular carcinoma
Xiang-yu Zhong et al.
GENE (2012)
Melanoma: from mutations to medicine
Hensin Tsao et al.
GENES & DEVELOPMENT (2012)
Copy Number Defects of G1-Cell Cycle Genes in Neuroblastoma are Frequent and Correlate with High Expression of E2F Target Genes and a Poor Prognosis
Jan J. Molenaar et al.
GENES CHROMOSOMES & CANCER (2012)
Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1
Xiaoping Zhao et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Cyclin-Dependent Kinase 16/PCTAIRE Kinase 1 Is Activated by Cyclin Y and Is Essential for Spermatogenesis
Petra Mikolcevic et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
Interaction of Cyclin-Dependent Kinase 12/CrkRS with Cyclin K1 Is Required for the Phosphorylation of the C-Terminal Domain of RNA Polymerase II
S. -W. Grace Cheng et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity.
L. M. Gelbert et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma
Asli Nar et al.
MEDICAL ONCOLOGY (2012)
CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells
Jian-Hua Yu et al.
ONCOLOGY REPORTS (2012)
p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity
Lingyan Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Cdk5: a multifaceted kinase in neurodegenerative diseases
Zelda H. Cheung et al.
TRENDS IN CELL BIOLOGY (2012)
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
D. Mahadevan et al.
ANNALS OF ONCOLOGY (2011)
Cyclin-Dependent Kinases in Brain Development and Disease
Susan C. Su et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 27 (2011)
Phosphorylation of human DNMT1: Implication of cyclin-dependent kinases
Genevieve Lavoie et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors
Caroline Corbel et al.
BIOTECHNOLOGY JOURNAL (2011)
An in silico approach for the discovery of CDK5/p25 interaction inhibitors
Bing Zhang et al.
BIOTECHNOLOGY JOURNAL (2011)
Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9
Nina Berberich et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
Georg Feldmann et al.
CANCER BIOLOGY & THERAPY (2011)
Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma Functional analysis and molecular targeting of cyclin-dependent kinase family members in advanced melanoma
Christopher Abdullah et al.
CELL CYCLE (2011)
Cyclin-Dependent Kinase 5 Is Amplified and Overexpressed in Pancreatic Cancer and Activated by Mutant K-Ras
John P. Eggers et al.
CLINICAL CANCER RESEARCH (2011)
Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection
G. Nemeth et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Peptides or Small Molecules? Different Approaches to Develop More Effective CDK Inhibitors
D. Cirillo et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I)
Xavier Morelli et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2011)
Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with differentiation during neurogenesis
Fahad Ali et al.
DEVELOPMENT (2011)
The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
Dalibor Blazek et al.
GENES & DEVELOPMENT (2011)
Cyclin-dependent Kinase 1 (CDK1)-mediated Phosphorylation of Enhancer of Zeste 2 (Ezh2) Regulates Its Stability
Susan C. Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
The CDK inhibitors in cancer research and therapy
Jonas Cicenas et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Cdk1 phosphorylation of the kinetochore protein Nsk1 prevents error-prone chromosome segregation
Jun-Song Chen et al.
JOURNAL OF CELL BIOLOGY (2011)
Dysregulation of CDK8 and Cyclin C in tumorigenesis
Wu Xu et al.
JOURNAL OF GENETICS AND GENOMICS (2011)
Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
William W. Lockwood et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4
Hilmar M. Warenius et al.
MOLECULAR CANCER (2011)
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine
E. Walsby et al.
LEUKEMIA (2011)
CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells
Yongkun Wei et al.
NATURE CELL BIOLOGY (2011)
Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease
Alan S. L. Wong et al.
NATURE CELL BIOLOGY (2011)
Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis
Jun-Li Liu et al.
MEDICAL ONCOLOGY (2011)
CYY-1/Cyclin Y and CDK-5 Differentially Regulate Synapse Elimination and Formation for Rewiring Neural Circuits
Mikyoung Park et al.
NEURON (2011)
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility
W. K. C. Leung et al.
ONCOGENE (2011)
PHYSIOLOGICAL RELEVANCE OF CELL CYCLE KINASES
Marcos Malumbres
PHYSIOLOGICAL REVIEWS (2011)
A Melanoma Molecular Disease Model
Smruti J. Vidwans et al.
PLOS ONE (2011)
Loss of Cytoplasmic CDK1 Predicts Poor Survival in Human Lung Cancer and Confers Chemotherapeutic Resistance
Chunyu Zhang et al.
PLOS ONE (2011)
Cyclin D as a therapeutic target in cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2011)
Structural and Functional Analysis of Cyclin D1 Reveals p27 and Substrate Inhibitor Binding Requirements
Shu Liu et al.
ACS CHEMICAL BIOLOGY (2010)
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma
Violetta V. Leshchenko et al.
BLOOD (2010)
Value of Integrated Positron Emission Tomography Revised Using a Phantom Study to Evaluate Malignancy Grade of Lung Adenocarcinoma A Multicenter Study
Haruhiko Nakayama et al.
CANCER (2010)
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Marta Puyol et al.
CANCER CELL (2010)
Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 Methyltransferase
Priya Aggarwal et al.
CANCER CELL (2010)
Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling
Georg Feldmann et al.
CANCER RESEARCH (2010)
Two Cyclin-Dependent Kinase Pathways Are Essential for Polarized Trafficking of Presynaptic Components
Chan-Yen Ou et al.
CELL (2010)
Cooperativity of Cdk4R24C and Ras in melanoma development
Rachna Chawla et al.
CELL CYCLE (2010)
Structural dissection of cyclin dependent kinases regulation and protein recognition properties
Graziano Lolli
CELL CYCLE (2010)
Cyclin-C-dependent cell-cycle entry is required for activation of non-homologous end joining DNA repair in postmitotic neurons
A. Tomashevski et al.
CELL DEATH AND DIFFERENTIATION (2010)
Cyclin-dependent kinase 9-cyclin K functions in the replication stress response
David S. Yu et al.
EMBO REPORTS (2010)
Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors
Richard M. Eglen et al.
EXPERT OPINION ON DRUG DISCOVERY (2010)
Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA
Syuzo Kaneko et al.
GENES & DEVELOPMENT (2010)
CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1
Bartlomiej Bartkowiak et al.
GENES & DEVELOPMENT (2010)
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Leslie Crews et al.
HUMAN MOLECULAR GENETICS (2010)
Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication
Maria D. Begnami et al.
HUMAN PATHOLOGY (2010)
Cdk5 Nuclear Localization Is p27-dependent in Nerve Cells IMPLICATIONS FOR CELL CYCLE SUPPRESSION AND CASPASE-3 ACTIVATION
Jie Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A 24-Residue Peptide (p5), Derived from p35, the Cdk5 Neuronal Activator, Specifically Inhibits Cdk5-p25 Hyperactivity and Tau Hyperphosphorylation
Ya-Li Zheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Cell Cycle-dependent Regulation of the Forkhead Transcription Factor FOXK2 by CDK.Cyclin Complexes
Anett Marais et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Wei-Gang Tong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cdk5 Suppresses the Neuronal Cell Cycle by Disrupting the E2F1-DP1 Complex
Jie Zhang et al.
JOURNAL OF NEUROSCIENCE (2010)
AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples
Matthew S. Squires et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Driving the cell cycle with a minimal CDK control network
Damien Coudreuse et al.
NATURE (2010)
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8
Avnish Kapoor et al.
NATURE (2010)
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2
Shuai Chen et al.
NATURE CELL BIOLOGY (2010)
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
L. Santo et al.
ONCOGENE (2010)
No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro
Dylan W. Peterson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Kamil Paruch et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Specific Overexpression of Cyclin E·CDK2 in Early Preinvasive and Primary Breast Tumors in Female ACI Rats Induced by Estrogen
S. John Weroha et al.
Hormones & Cancer (2010)
EPIGENETICS AND GENETICS A census of amplified and overexpressed human cancer genes
Thomas Santarius et al.
NATURE REVIEWS CANCER (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
Cyclin E deregulation is an early event in the development of breast cancer
Alexandra Shaye et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
High cyclin B1 expression is associated with poor survival in breast cancer
K. Aaltonen et al.
BRITISH JOURNAL OF CANCER (2009)
Revving the Throttle on an Oncogene: CDK8 Takes the Driver Seat
Ron Firestein et al.
CANCER RESEARCH (2009)
Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression
Hannah Wingate et al.
CELL CYCLE (2009)
ATP-Noncompetitive Inhibitors of CDK-Cyclin Complexes
Mar Orzaez et al.
CHEMMEDCHEM (2009)
Truncation and Optimisation of Peptide Inhibitors of Cyclin-Dependent Kinase 2-Cyclin A Through Structure-Guided Design
George Kontopidis et al.
CHEMMEDCHEM (2009)
Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy
Merry Y. Zhao et al.
CLINICAL CANCER RESEARCH (2009)
Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer
Clay E. S. Comstock et al.
CLINICAL CANCER RESEARCH (2009)
Cell Cycle Control of Wnt Receptor Activation
Gary Davidson et al.
DEVELOPMENTAL CELL (2009)
The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model
A. Scholz et al.
GUT (2009)
A Novel Class of Cyclin-dependent Kinase Inhibitors Identified by Molecular Docking Act through a Unique Mechanism
Patrick Corsino et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A Conserved Phosphorylation Site within the Forkhead Domain of FoxM1B Is Required for Its Activation by Cyclin-CDK1
Yi-Ju Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Nuclear Cyclin D1: An Oncogenic Driver in Human Cancer
Jong Kyong Kim et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population
Hyo Seon Choi et al.
JOURNAL OF HUMAN GENETICS (2009)
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Kate F. Byth et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
Matthew S. Squires et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth
Laurence Crombez et al.
NUCLEIC ACIDS RESEARCH (2009)
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
A. Satyanarayana et al.
ONCOGENE (2009)
Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome
E. K. A. Millar et al.
ONCOGENE (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol
Ilija Androic et al.
BMC CANCER (2008)
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
Elizabeth Iorns et al.
CANCER CELL (2008)
Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion
Alan P. Brown et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression
Keiran S. M. Smalley et al.
CANCER RESEARCH (2008)
A novel therapeutic combination using PD 0332991 and bortezomib: Study in the 5T33MM myeloma model
Eline Menu et al.
CANCER RESEARCH (2008)
Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation
Duo Zheng et al.
CANCER RESEARCH (2008)
An unusual member of the Cdk family: Cdk5
Fatema A. Dhariwala et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2008)
Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer
Saby George et al.
CLINICAL LUNG CANCER (2008)
CDK inhibitors: Cell cycle regulators and beyond
Arnaud Besson et al.
DEVELOPMENTAL CELL (2008)
Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients
Rong Li et al.
HUMAN PATHOLOGY (2008)
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design
Paul G. Wyatt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
CDK targets Sae2 to control DNA-end resection and homologous recombination
Pablo Huertas et al.
NATURE (2008)
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Ron Firestein et al.
NATURE (2008)
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
K. Bettayeb et al.
ONCOGENE (2008)
CDK inhibitors in cancer therapy: what is next?
Marcos Malumbres et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
Shudong Wang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Interaction between the Cdk2/Cyclin a complex and a small molecule derived from the pRb2/p130 spacer domain
Antonio Giordano et al.
CELL CYCLE (2007)
Flavopiridol in the treatment of chronic lymphocytic leukemia
Beth A. Christian et al.
CURRENT OPINION IN ONCOLOGY (2007)
Haploinsufficiency of the cdc21 gene contributes to skin cancer development in mice
Anupama Chandramouli et al.
CARCINOGENESIS (2007)
Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases
Karima Bettayeb et al.
CANCER RESEARCH (2007)
Cdk1 is sufficient to drive the mammalian cell cycle
David Santamaria et al.
NATURE (2007)
A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers
D. Ross Camidge et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Andrei Goga et al.
NATURE MEDICINE (2007)
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor
Takashi Suzuki et al.
CANCER SCIENCE (2007)
A census of mitotic cancer genes:: new insights into tumor cell biology and cancer therapy
Ignacio Perez de Castro et al.
CARCINOGENESIS (2007)
A non-covalent peptide-based carrier for in vivo delivery of DNA mimics
May C. Morris et al.
NUCLEIC ACIDS RESEARCH (2007)
A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo
L. Bagella et al.
ONCOGENE (2007)
CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing
Hung-Hsi Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Patterns of somatic mutation in human cancer genomes
Christopher Greenman et al.
NATURE (2007)
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
Kalpana S. Joshi et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors
Bart A. Jessen et al.
JOURNAL OF APPLIED TOXICOLOGY (2007)
P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-reasistant cells and significant in vivo efficacy in tumor models
Kalpana S. Joshi et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Chemical genetics: Where genetics and pharmacology meet
Zachary A. Knight et al.
CELL (2007)
Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation
Oliver Gautschi et al.
LUNG CANCER (2007)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Adrian Wiestner et al.
BLOOD (2007)
Abrogation of signal-dependent activation of the cdk9/cyclin T2a complex in human RD rhabdomyosarcoma cells
C. Simone et al.
CELL DEATH AND DIFFERENTIATION (2007)
Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A
Nuria Canela et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity
Xin-Jie Chu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
In vitro and in vivo activity of R547:: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
Wanda DePinto et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1
S. Benzeno et al.
ONCOGENE (2006)
Extraneuronal roles of cyclin-dependent kinase 5
Jesusa L. Rosales et al.
BIOESSAYS (2006)
RB and cell cycle progression
C. Giacinti et al.
ONCOGENE (2006)
Malignant melanoma: genetics and therapeutics in the genomic era
Lynda Chin et al.
GENES & DEVELOPMENT (2006)
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells
Christopher J. Strock et al.
CANCER RESEARCH (2006)
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
Linda B. Baughn et al.
CANCER RESEARCH (2006)
Centrosome abnormalities are frequently observed in non-small-cell lung cancer and are associated with aneuploidy and cyclin E overexpression
M. K. Koutsami et al.
JOURNAL OF PATHOLOGY (2006)
Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621
SL Huang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1
Lyubomir T. Vassilev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709
G. Siemeister et al.
BIOMEDICINE & PHARMACOTHERAPY (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Discovery and evaluation of dual CDK1 and CDK2 inhibitors
M Payton et al.
CANCER RESEARCH (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
The when and wheres of CDC25 phosphatases
R Boutros et al.
CURRENT OPINION IN CELL BIOLOGY (2006)
Peptide aptamers as guides for small-molecule drug discovery
IC Baines et al.
DRUG DISCOVERY TODAY (2006)
Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation
HH Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo
J Yuan et al.
ONCOGENE (2006)
Update on the molecular biology of mantle cell lymphoma
F Bertoni et al.
HEMATOLOGICAL ONCOLOGY (2006)
Cyclin D1: polymorphism, aberrant splicing and cancer risk
KE Knudsen et al.
ONCOGENE (2006)
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation
CJ Burd et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Peptide inhibitors of protein kinases - discovery, characterisation and use
MA Bogoyevitch et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Exploiting structural principles to design cyclin-dependent kinase inhibitors
M Noble et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma
F Mendrzyk et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Secrets of a double agent: CDK7 in cell-cycle control and transcription
RP Fisher
JOURNAL OF CELL SCIENCE (2005)
Mammalian cyclin-dependent kinases
M Malumbres et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
The in vitro and in vivo effects of JNJ-7706621:: A dual inhibitor of cyclin-dependent kinases and aurora kinases
S Emanuel et al.
CANCER RESEARCH (2005)
Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death
MJ O'Hare et al.
JOURNAL OF NEUROSCIENCE (2005)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Roscovitine targets, protein kinases and pyridoxal kinase
S Bach et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
2-Aminoquinazoline inhibitors of cyclin-dependent kinases
Y Bathini et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation
M Pennati et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: An immunohistochemical study
Hui Yue et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Expression of cyclin A1 and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcome
J Ekberg et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Cooperation between Cdk4 and p27kip1 in tumor development:: A preclinical model to evaluate cell cycle inhibitors with therapeutic activity
R Sotillo et al.
CANCER RESEARCH (2005)
Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation
C Gondeau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
PL Toogood et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery
Y Pommier et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats
AV Kamath et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Clinical anticancer drug development: targeting the cyclin-dependent kinases
C Benson et al.
BRITISH JOURNAL OF CANCER (2005)
A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons
YL Zheng et al.
EMBO JOURNAL (2005)
The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-xL protein
MR Bhonde et al.
ONCOGENE (2005)
Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity
AKY Fu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cyclin C/Cdk3 promotes Rb-dependent G0 exit
SJ Ren et al.
CELL (2004)
Cyclin E deregulation alters the biologic properties of ovarian cancer cells
I Bedrosian et al.
ONCOGENE (2004)
Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum
M Gompel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream
MR Arkin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells
RM Harwell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase -: 2.: N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent
RN Misra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation
C Bellan et al.
JOURNAL OF PATHOLOGY (2004)
Emerging classes of protein-protein interaction inhibitors and new tools for their development
L Pagliaro et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2004)
Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma
Y Dobashi et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Living with or without cyclins and cyclin-dependent kinases
CJ Sherr et al.
GENES & DEVELOPMENT (2004)
Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes
MJI Andrews et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2004)
Molecular alterations associated with cyclin D1 overexpression in endometrial cancer
G Moreno-Bueno et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas
WT Su et al.
CANCER GENETICS AND CYTOGENETICS (2004)
Low-molecular-weight cyclin E: the missing link between biology and clinical outcome
S Akli et al.
BREAST CANCER RESEARCH (2004)
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease
PD Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles
JC Cruz et al.
NEURON (2003)
SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2
DJ Moshinsky et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Progression through the G1-phase of the on-going cell cycle
J Boonstra
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
Diversity of protein-protein interactions
IMA Nooren et al.
EMBO JOURNAL (2003)
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
K Vermeulen et al.
CELL PROLIFERATION (2003)
CDK11 complexes promote pre-mRNA splicing
DL Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Binding of small molecules to an adaptive protein-protein interface
MR Arkin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Active cyclin B1-Cdk1 first appears on centrosomes in prophase
M Jackman et al.
NATURE CELL BIOLOGY (2003)
Small molecules as inhibitors of cyclin-dependent kinases
A Huwe et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2003)
Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis
MD Nguyen et al.
NEUROSIGNALS (2003)
Role of cdk5 in the pathogenesis of Alzheimer's disease
LF Lau et al.
NEUROSIGNALS (2003)
Highly potent p21WAF1-derived peptide inhibitors of CDK-mediated pRb phosphorylation:: Delineation and structural insight into their interactions with cyclin A
DI Zheleva et al.
JOURNAL OF PEPTIDE RESEARCH (2002)
Cyclin a correlates with carcinogenesis and metastasis, and P27kip1 correlates with lymphatic invasion, in colorectal neoplasms
JQ Li et al.
HUMAN PATHOLOGY (2002)
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
TG Davies et al.
NATURE STRUCTURAL BIOLOGY (2002)
A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells
YL Zheng et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2002)
Pharmacological inhibitors of cyclin-dependent kinases
M Knockaert et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2002)
Kinetic mechanism of activation of the Cdk2/cyclin A complex
MC Morris et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cellular effects of purvalanol A: A specific inhibitor of cyclin-dependent kinase activities
N Villerbu et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes
A Ho et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2002)
Regulation of cyclin-Cdk activity in mammalian cells
AJ Obaya et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2002)
Complexities in the development of cyclin-dependent kinase inhibitor drugs
EA Sausville
TRENDS IN MOLECULAR MEDICINE (2002)
Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors
R Sotillo et al.
EMBO JOURNAL (2001)
To cycle or not to cycle: A critical decision in cancer
M Malumbres et al.
NATURE REVIEWS CANCER (2001)
Cyclin-dependent kinase 5 promotes insulin exocytosis
L Lilja et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Structure and regulation of the CDK5-p25nck5a complex
C Tarricone et al.
MOLECULAR CELL (2001)
Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors
D Wang et al.
JOURNAL OF VIROLOGY (2001)
Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments
AD Alonso et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix
TH Cheung et al.
CANCER LETTERS (2001)
Cell cycle and biochemical effects of PD 0183812 - a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6
DW Fry et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation
DK Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4
R Soni et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions
J Georgieva et al.
JOURNAL OF CLINICAL PATHOLOGY (2001)
被撤回的出版物: Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors (Retracted Article. See vol 298, pg 2327, 2002)
ST Davis et al.
SCIENCE (2001)
Kinetic basis for activation of CDK2/clyclin A by phosphorylation
JC Hagopian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease -: A property common to most cycline-dependent kinase inhibitors?
S Leclerc et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors
PD Jeffrey et al.
GENES & DEVELOPMENT (2000)
Novel splice variants of cyclin E with altered substrate specificity
Donald C. Porter et al.
NUCLEIC ACIDS RESEARCH (2000)
Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics
PM Fischer et al.
CURRENT MEDICINAL CHEMISTRY (2000)
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases
M Barvian et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
SH Chao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
The incredible life and times of biological cells
P Nurse
SCIENCE (2000)
TFIIH is negatively regulated by cdk8-containing mediator complexes
S Akoulitchev et al.
NATURE (2000)
Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product
R Soni et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
CE Arris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25
G Kusakawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Neurotoxicity induces cleavage of p35 to p25 by calpain
MS Lee et al.
NATURE (2000)
Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors
GR Rosania et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2000)
Inhibition of cyclin-dependent kinases, GSK-3 beta and CK1 by hymenialdisine, a marine sponge constituent
L Meijer et al.
CHEMISTRY & BIOLOGY (2000)
Preclinical and clinical development of cyclin-dependent kinase modulators
AM Senderowicz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)